Development of the Bowman-Birk Inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk Inhibitor concentrate treatment

Laryngoscope

Volumn 113, Issue 10, 2003, Pages 1687-1702

  Armstrong, William B ^a,c   Wan, X Steven ^d   Kennedy, Ann R ^d   Taylor, Thomas H ^b   Meyskens Jr , Frank L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anticarcinogenic agents; Bowman Birk soybean; Chemoprevention; Drug therapy; ErbB 2; Oral leukoplakia; Receptor; Trypsin inhibitor

Indexed keywords

BOWMAN BIRK INHIBITOR; MONOCLONAL ANTIBODY; PROTEINASE; PROTEINASE INHIBITOR; RETINOID;

ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; ENZYME ACTIVITY; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; MOUTH CANCER; MOUTH MUCOSA; ONCOGENE NEU; ORAL BIOPSY; PHASE 2 CLINICAL TRIAL; PRECANCER; PRIORITY JOURNAL; REVIEW; SOYBEAN;

NON-PROGRAMMATIC;

ALPHA-AMYLASE; ANIMALS; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA, ORAL; PLANT PROTEINS; RECEPTOR, ERBB-2; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN; TRYPSIN INHIBITORS;

EID: 0141752847     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-200310000-00007     Document Type: Review

References (163)

1. Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988;41:184-197.
2. Macfarlane GJ, Boyle P, Scully C. Rising mortality from cancer of the tongue in young Scottish males [letter]. Lancet 1987;2:912.
3. Hindle I, Downer MC, Speight PM. The epidemiology of oral cancer. Br J Oral Maxillofac Surg 1996;34:471-476.
4. Nieto A, Ramos MR. Rising trends in oral cancer mortality in Spain, 1975-94. J Oral Pathol Med 2002;31:147-152.
5. Chen JK, Eisenberg E, Krutchkoff DJ, Katz RV. Changing trends in oral cancer in the United States, 1935 to 1985: a Connecticut study. J Oral Maxillofac Surg 1991;49:1152-1158.
6. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
7. Silverman S, Jr. Demographics and occurrence of oral and pharyngeal cancers: the outcomes, the trends, the challenge. J Am Dent Assoc 2001;132:7S-11S.
8. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001;93:824-842.
9. Kotwall C, Razack MS, Sako K, Rao U. Multiple primary cancers in squamous cell cancer of the head and neck. J Surg Oncol 1989;40:97-99.
10. Spitz MR. Epidemiology and risk factors for head and neck cancer. Semin Oncol 1994;21:281-288.
11. Shaha AR. Cancer of the head and neck. In: Murphy GP, Lawrence W, Lenhard RE, eds. American Cancer Society Textbook of Clinical Oncology, 2nd ed. Atlanta: American Cancer Society; 1995:355-377.
12. Trends in cigarette smoking among high school students: United States, 1991-2001. MMWR 2002;51:409-412.
13. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer [Comments]. N Engl J Med 1993;328:184-194.
14. Guggenheimer J, Verbin RS, Johnson JT, Horkowitz CA, Myers EN. Factors delaying the diagnosis of oral and oropharyngeal carcinomas. Cancer 1989;64:932-935.
15. Smart CR. Screening for cancer of the aerodigestive tract. Cancer 1993;72:1061-1065.
16. Examination for oral cancer: United States, 1992. MMWR 1994;43:198-200.
17. Chu KC, Tarone RE, Kessler LG, et al. Recent trends in US breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 1996;88:1571-1579.
18. Manual for Staging of Cancer, 4th ed. Philadelphia: JB Lippincott, 1992.
19. Mikkilineni R, Weinstock MA. Epidemiology. In: Sober AJ, Haluska FG, eds. American Cancer Society Atlas of Clinical Oncology: Skin Cancer. Hamilton, Ontario: BC Decker; 2001:1-15.
20. Mashberg A, Meyers H. Anatomical site and size of 222 early asymptomatic oral squamous cell carcinomas: a continuing prospective study of oral cancer, II. Cancer 1976;37:2149-2157.
21. Bertram JS, Kolonel LN, Meyskens FL, Jr. Rationale and strategies for chemoprevention of cancer in humans. Cancer Res 1987;47:3012-3031.
22. Meyskens FL, Jr. Biology and intervention of the premalignant process. Cancer Bull 1991;43:475-480.
23. Garewal HS, Meyskens FL, Jr. Chemoprevention of cancer. Hematol Oncol Clin North Am 1991;5:69-77.
24. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488-2492.
25. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:229-233.
26. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976;35:1332-1338.
27. Hong WK, Lippman SM. Cancer chemoprevention. J Natl Cancer Inst Monogr 1995:49-53.
28. Willett WC, MacMahon B. Diet and cancer: an overview-part I. N Engl J Med 1984;310:633-639.
29. Willett WC, MacMahon B. Diet and cancer: an overview-part II. N Engl J Med 1984;310:697-702.
30. Kelloff GJ, Malone WF, Boone CW, Sigman CC, Fay JR. Progress in applied chemoprevention research. Semin Oncol 1990;17:438-455.
31. Meyskens FL, Jr. Chemoprevention of human cancer: a reasonable strategy? Recent Results Cancer Res 1999;151:113-121.
32. Meyskens FL, Jr. Criteria for implementation of large and multiagent clinical chemoprevention trials. J Cell Biochem Suppl 2000;34:115-120.
33. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
34. Bouquot JE, Gorlin RJ. Leukoplakia, lichen planus, and other oral keratoses in 23,616 white Americans over the age of 35 years. Oral Surg Oral Med Oral Pathol Oral Radiol 1986;61:373-381.
35. Knapp MJ. Oral disease in 181,338 consecutive oral examinations. J Am Dent Assoc 1971;83:1288-1293.
36. Tomar SL, Winn DM, Swango PA, Giovino GA, Kleinman DV. Oral mucosal smokeless tobacco lesions among adolescents in the United States. J Dent Res 1997;76:1277-1286.
37. Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Prevalence study of oral white lesions with special reference to a new definition of oral leukoplakia. Eur J Cancer B Oral Oncol 1996;32B:416-419.
38. Silverman S, Jr. Diagnosis and management of leukoplakia and premalignant lesions. Oral Maxillofac Surg Clin North Am 1998;10:13-23.
39. Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol 1998;34:270-275.
40. Shafer WG, Waldron CA. Erythroplakia of the oral cavity. Cancer 1975;36:1021-1028.
41. Mashberg A, Barsa P. Screening for oral and oropharyngeal squamous carcinomas. CA Cancer J Clin 1984;34:262-268.
42. Mashberg A, Samit AM. Early detection, diagnosis, and management of oral and oropharyngeal cancer. CA Cancer J Clin 1989;39:67-88.
43. Roed-Petersen B. Cancer development in oral leukoplakia: follow-up of 331 patients [abstract]. J Dent Res 1971;50:711.
44. Bánóczy J. Follow-up studies in oral leukoplakia. J Maxillofac Surg 1977;5:69-75.
45. Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. Cancer 1984;53:563-568.
46. Hansen LS, Olson JA, Silverman SJ. Proliferative verrucous leukoplakia. Oral Surg Oral Med Oral Pathol Oral Radiol 1985;60:285-298.
47. Silverman S, Jr., Gorsky M. Proliferative verrucous leukoplakia: a follow-up study of 54 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;84:154-157.
48. Mincer HH, Coleman SA, Hopkins KP. Observations on the clinical characteristics of oral lesions showing histologic epithelial dysplasia. Oral Surg Oral Med Oral Pathol 1972;33:389-399.
49. Waldron CA, Shafer WG. Leukoplakia revisited: a clinicopathologic study of 3256 oral leukoplakias. Cancer 1975;36:1386-1392.
50. Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000;6:1702-1710.
51. Krinsky NI. Actions of carotenoids in biological systems. Annu Rev Nutr 1993;13:561-587.
52. Stich HF, Rosin MP, Hornby AP, Mathew B, Sankaranarayanan R, Nair MR. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. Int J Cancer 1988;42:195-199.
53. Zaridze D, Evstifeeva T, Boyle P. Chemoprevention of oral leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer. Ann Epidemiol 1993;3:225-234.
54. Garewal HS, Katz RV, Meyskens F, et al. Beta-carotene produces sustained remissions in patients with oral leukoplakia: results of a multicenter prospective trial. Arch Otolaryngol Head Neck Surg 1999;125:1305-1310.
55. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis [Comments]. N Engl J Med 1993;328:15-20.
56. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-1149.
57. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers: the Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994;330:1029-1035.
58. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial [Comments]. J Natl Cancer Inst 1996;88:1550-1559.
59. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease [Comments]. N Engl J Med 1996;334:1150-1155.
60. Greenberg ER, Baron JA, Stukel TA, et al. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin: The Skin Cancer Prevention Study Group. N Engl J Med 1990;323:789-795 [erratum: N Engl J Med 1991;325:1324].
61. Greenberg ER, Baron JA, Stukel TA, et al. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin: The Skin Cancer Prevention Study Group. N Engl J Med 1990;323:789-795 [erratum: N Engl J Med 1991;325:1324].
62. Greenberg ER, Baron JA, Tosteson TD, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma: Polyp Prevention Study Group. N Engl J Med 1994;331:141-147.
63. Romney SL, Ho GYF, Palan PR, et al. Effects of beta carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol Oncol 1997;65:483-492.
64. Lippman SM, Kessler JF, Meyskens FL, Jr. Retinoids as preventive and therapeutic anticancer agents: part I. Cancer Treat Rep 1987;71:391-405.
65. Lippman SM, Kessler JF, Meyskens FL, Jr. Retinoids as preventive and therapeutic anticancer agents: part II. Cancer Treat Rep 1987;71:493-515.
66. Lotan R, Xu XC, Lippman SM, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995;332:1405-1410.
67. Xu XC, Zile MH, Lippman SM, et al. Anti-Retinoic Acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. Cancer Res 1995;55:5507-5511.
68. Lippman SM, Spitz M, Trizna Z, Benner SE, Hong WK. Epidemiology, biology, and chemoprevention of aerodigestive cancer. Cancer 1994;74:2719-2725.
69. Hong WK, Endicott J, Itri LM, et al. 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501-1505.
70. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck [Comments]. N Engl J Med 1990;323:795-801.
71. Benner SE, Pajak TF, Lippman SM, Earley C, Hong WK. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst 1994;86:140-141.
72. Papadimitrakopoulou VA, Clayman GL, Shin DM, et al. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 1999;125:1083-1089.
73. Armstrong WB, Meyskens FL, Jr. Chemoprevention of head and neck cancer. Otolaryngol Head Neck Surg 2000;122:728-735.
74. Vanaman TC, Bradshaw RA. Proteases in cellular regulation minireview series. J Biol Chem 1999;274:20047.
75. Silverman GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins: evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001;276:33293-33296.
76. Nakashima T, Pak SC, Silverman GA, Spring PM, Frederick MJ, Clayman GL. Genomic cloning, mapping, structure and promoter analysis of HEADPIN, a serpin which is down-regulated in head and neck cancer cells. Biochim Biophys Acta 2000;1492:441-446.
77. Spring P, Nakashima T, Frederick M, Henderson Y, Clayman G. Identification and cDNA cloning of headpin, a novel differentially expressed serpin that maps to chromosome 18q. Biochem Biophys Res Commun 1999;264:299-304.
78. Maass N, Hojo T, Zhang M, Sager R, Jonat W, Nagasaki K. Maspin: a novel protease inhibitor with tumor-suppressing activity in breast cancer. Acta Oncol 2000;39:931-934.
79. Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ, Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci U S A 1996;93:11669-11674.
80. Xia W, Lau YK, Hu MC, et al. High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene 2000;19:2398-2403.
81. Silverman GA, Bartuski AJ, Cataltepe S, et al. SCCA1 and SCCA2 are proteinase inhibitors that map to the serpin cluster at 18q21.3. Tumour Biol 1998;19:480-487.
82. Birk Y. Protease inhibitors of plant origin and role of protease inhibitors in human nutrition: overview. In: Troll W, Kennedy AR, eds. Protease Inhibitors as Cancer Chemopreventive Agents. New York: Plenum; 1993:97-106.
83. Kunitz M. Crystallization of a trypsin inhibitor from soybeans. Science 1945;101:668-669.
84. Ostergaard H, Rasmussen SK, Roberts TH, Hejgaard J. Inhibitory serpins from wheat grain with reactive centers resembling glutamine-rich repeats of prolamin storage proteins: cloning and characterization of five major molecular forms. J Biol Chem 2000;275:33272-33279.
85. Correa P. Epidemiological correlations between diet and cancer frequency. Cancer Res 1981;41:3685-3690.
86. Winn DM, Ziegler RG, Pickle LW, Gridley G, Blot WJ, Hoover RN. Diet in the etiology of oral and pharyngeal cancer among women from the Southern United States. Cancer Res 1984;44:1216-1222.
87. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA 2001;285:769-776.
88. Clark G. Recent studies cloud link between diet and cancer. J Natl Cancer Inst 2000;92:1794-1795.
89. Kennedy AR. Chemopreventive agents: protease inhibitors. Pharmacol Ther 1998;78:167-209.
90. Kennedy AR. Cancer prevention by protease inhibitors. Prev Med 1993;22:796-811.
91. Kennedy AR. Overview: anticarcinogenic activity of protease inhibitors. In: Troll W, Kennedy AR, eds. Protease Inhibitors as Cancer Chemopreventive Agents. New York: Plenum; 1993:9-64.
92. Kennedy AR. The evidence for soybean products as cancer preventive agents [Comments]. J Nutr 1995;125:733S-743S.
93. Kennedy AR, Little JB. Effects of protease inhibitors on radiation transformation in vitro. Cancer Res 1981;41:2103-2108.
94. Yavelow J, Collins M, Birk Y, Troll W, Kennedy AR. Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress x-ray-induced transformation in vitro. Proc Natl Acad Sci U S A 1985;82:5395-5399.
95. Messadi DV, Billings P, Schklar G, Kennedy AR. Inhibition of oral carcinogenesis by a protease inhibitor. J Natl Cancer Inst 1986;76:447-452.
96. Birk Y. Proteinase inhibitors from plant sources. Methods Enzymol 1976;45:695-697.
97. Birk Y. The Bowman-Birk protease inhibitor: trypsin- and chymotrypsin-inhibitor from soybeans. Int J Peptide Protein Res 1985;25:113-131.
98. Fournier DB, Erdman JW, Gordon GB. Soy, its components, and cancer prevention: a review of the in vitro, animal, and human data. Cancer Epidemiol Biomarkers Prev 1998;7:1055-1065.
99. Messina MJ, Persky V, Setchell KDR, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994;21:113-131.
100. St. Clair WH, Billings PC, Carew JA, Keller-McGandy C, Newberne P, Kennedy AR. Suppression of dimethylhydrazine-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor. Cancer Res 1990;50:580-586.
101. Birk Y. Purification and some properties of a highly active inhibitor of trypsin and a-chymotrypsin from soybeans. Biochem Biophys Acta 1961;54:191-197.
102. Yavelow J, Finlay TH, Kennedy AR, Troll W. Bowman-Birk soybean protease inhibitor as an anticarcinogen. Cancer Res 1983;43:2454s-2459s.
103. Blondell JM. Urban-rural factors affecting cancer mortality in Kentucky: 1950-1969. Cancer Detect Prev 1988;11:209-223.
104. Chen P, Rose J, Love R, Wei CH, Wang BC. Reactive sites of an anticarcinogenic Bowman-Birk proteinase inhibitor are similar to other trypsin inhibitors. J Biol Chem 1992;267:1990-1994.
105. Voss RH, Ermler U, Essen LO, Wenzl G, Kim YM, Flecker P. Crystal structure of the bifunctional soybean Bowman-Birk inhibitor at 0.28-nm resolution: structural peculiarities in a folded protein conformation. Eur J Biochem 1996;242:122-131.
106. Birk Y. Trypsin and chymotrypsin inhibitors from soybeans. Methods Enzymol 1976;45:700-707.
107. Kennedy AR, Szuhaj BF, Newberne PM, Billings PC. Preparation and production of a cancer chemopreventive agent, Bowman-Birk Inhibitor Concentrate. Nutr Cancer 1993;19:281-302.
108. Baturay NZ, Kennedy AR. Pyrene acts as a cocarcinogen with the carcinogens benzo[a]pyrene, beta-propiolactone and radiation in the induction of malignant transformation of cultured mouse fibroblasts: soybean extract containing the Bowman-Birk inhibitor acts as an anticarcinogen. Cell Biol Toxicol 1986;2:21-32.
109. Kennedy AR. The conditions for the modification of radiation transformation in vitro by a tumor promoter and protease inhibitors. Carcinogenesis 1985;6:1441-1445.
110. Kennedy AR. The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am J Clin Nutr 1998;68:1406S-1412S.
111. Odani S, Ikenaka TJ. Scission of soybean Bowman-Birk proteinase inhibitor into two small fragments having either trypsin or chymotrypsin inhibitor activity. J Biochem (Tokyo) 1973;74:857-860.
112. Hooper JD, Clements JA, Quigley JP, Antalis TM. Type II transmembrane serine proteases: insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem 2001;276:857-860.
113. Billings PC, Habres JM. A growth-regulated protease activity that is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor. Proc Natl Acad Sci U S A 1992;89:3120-3124.
114. Billings PC, Carew JA, Keller-McGandy CE, Goldberg AL, Kennedy AR. A serine protease activity in C3H/10T1/2 cells that is inhibited by anticarcinogenic protease inhibitors. Proc Natl Acad Sci U S A 1987;84:4801-4805.
115. Habres JM, Billings PC. Intestinal epithelial cells contain a high molecular weight protease subject to inhibition by anticarcinogenic protease inhibitors. Cancer Lett 1992;63:135-142.
116. Moy LY, Billings PC. A proteolytic activity in a human breast cancer cell line which is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor. Cancer Lett 1994;85:205-210.
117. Billings PC, St Clair W, Owen AJ, Kennedy AR. Potential intracellular target proteins of the anticarcinogenic Bowman Birk protease inhibitor identified by affinity chromatography. Cancer Res 1988;48:1798-1802.
118. Yavelow J, Caggana M, Beck KA. Proteases occurring in the cell membrane: a possible cell receptor for the Bowman-Birk type of protease inhibitors. Cancer Res 1987;47:1598-1601.
119. Larionova NI, Gladysheva IP, Tikhonova TV, Kazanskaia NF. Inhibition of cathepsin G and human granulocyte elastase by multiple forms of Bowman-Birk type soybean inhibitor. In: Translations from Biokhimiya (Russian). New York: Plenum; 1994:1046-1052.
120. Ware JH, Wan XS, Rubin H, Schechter NM, Kennedy AR. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch Biochem Biophys 1997;344:133-138.
121. Tikhonova TV, Gladysheva IP, Kazanskaia NF, Larionova NI. Inhibition of elastin hydrolysis, catalyzed by human leukocyte elastase and cathepsin G, by the Bowman-Birk type soy inhibitor [Russian]. Biokhimiya 1994;59:1739-1745.
122. Gladysheva IP, Larionova NI, Gladyshev DP, Tikhonova TV, Kazanskaia NF. The classical Bowman-Birk soybean inhibitor is an effective inhibitor of human granulocyte alpha-chymotrypsin and cathepsin G. Biochem (Mosc) 1994;59:513-518.
123. 22 formation by activated human polymorphonuclear leukocytes. Carcinogenesis 1987;8:1207-1212.
124. Ware JH, Wan XS, Kennedy AR. Bowman-Birk inhibitor suppresses production of superoxide anion radicals in differentiated HL-60 cells. Nutr Cancer 1999;33:174-177.
125. Caggana M, Kennedy AR. c-fos mRNA levels are reduced in the presence of antipain and Bowman-Birk inhibitor. Carcinogenesis 1989;10:2145-2148.
126. St Clair WH, Billings PC, Kennedy AR. The effects of the Bowman-Birk protease inhibitor on c-myc expression and cell proliferation in the unirradiated and irradiated mouse colon. Cancer Lett 1990;52:145-152.
127. St Clair WH, St Clair DK. Effect of the Bowman-Birk protease inhibitor on the expression of oncogenes in the irradiated rat colon. Cancer Res 1991;51:4539-4543.
128. Chang JD, Li JH, Billings PC, Kennedy AR. Effects of protease inhibitors on c-myc expression in normal and transformed C3H 10T1/2 cell lines. Mol Carcinog 1990;3:226-232.
129. Gueven N, Dittmann K, Mayer C, Rodemann HP. The radioprotective potential of the Bowman-Birk protease inhibitor is independent of its secondary structure. Cancer Lett 1998;125:77-82.
130. Rothman SS, Wells H. Enhancement of pancreatic enzyme synthesis by pancreozymin. Am J Physiol 1967;213:215-218.
131. Mainz DL, Black O, Webster PD. Hormonal control of pancreatic growth. J Clin Invest 1973;52:2300-2304.
132. Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE, Meyskens FL, Jr. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev 2000;9:43-47.
133. Wan XS, Lu LJ, Anderson KE, Ware JH, Kennedy AR. Urinary excretion of Bowman-Birk inhibitor in humans after soy consumption as determined by a monoclonal antibody-based immunoassay. Cancer Epidemiol Biomarkers Prev 2000;9:741-747.
134. Armstrong WB, Kennedy AR, Wan XS, et al. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 2000;6:4684-4691.
135. Shin DM, Hittelman WN, Hong WK. Biomarkers in upper aerodigestive tract tumorigenesis: a review. Cancer Epidemiol Biomarkers Prev 1994;3:697-709.
136. Kim J, Shin DM. Biomarkers of squamous cell carcinoma of the head and neck. Histol Histopathol 1997;12:205-218.
137. Manzone H, Billings PC, Cummings WN, et al. Levels of proteolytic activities as intermediate marker endpoints in oral carcinogenesis. Cancer Epidemiol Biomarkers Prev 1995;4:521-527.
138. Brandt-Rauf PW. The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies. Mutat Res 1995;333:203-208.
139. Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986;319:230-234.
140. Slamon DJ, Gogolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancers. Science 1989;244:707-712.
141. Xia W, Lau YK, Zhang HZ, et al. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 1997;3:3-9.
142. Hou L, Shi D, Tu SM, Zhang HZ, Hung MC, Ling D. Oral cancer progression and c-erbB-2/neu proto-oncogene expression. Cancer Lett 1992;65:215-220.
143. Werkmeister R, Brandt B, Joos U. Aberrations of erbB-1 and erbB-2 oncogenes in non-dysplastic leukoplakias of the oral cavity. Br J Oral Maxillofac Surg 1999;37:477-480.
144. Wilkman TS, Hietanen JH, Malmstrom MJ, Konttinen YT. Immunohistochemical analysis of the oncoprotein c-erbB-2 expression in oral benign and malignant lesions. Int J Oral Maxillofac Surg 1998;27:209-212.
145. Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 1993;8:2917-2923.
146. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in Nih/3t3 cells. Science 1987;237:178-182.
147. Decker SJ. Epidermal growth factor-induced truncation of the epidermal growth factor receptor. J Biol Chem 1989;264:17641-17644.
148. Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-832.
149. Wu JT, Astill ME, Gagon SD, Bryson L. Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein. J Clin Lab Anal 1995;9:151-165.
150. Wu JT, Astill ME, Zhang P. Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers. J Clin Lab Anal 1993;7:31-40.
151. Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002;20:1467-1472.
152. Fisken J, Roulston JE, Beattie G, Hayes DF, Leonard RC. Investigation of the c-neu proto-oncogene related protein, p185, in the serum of primary epithelial ovarian cancer patients. Int J Gynecol Cancer 1992;2:134-140.
153. Wan XS, Meyskens FL, Jr., Armstrong WB, Taylor TH, Kennedy AR. Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor. Cancer Epidemiol Biomarkers Prev 1999;8:601-608.
154. Benner SE, Lippman SM, Wargovich MJ, et al. Micronuclei, a biomarker for chemoprevention trials: results of a randomized study in oral pre-malignancy. Int J Cancer 1994;59:457-459.
155. Sudbø J, Kildal W, Risberg B, Koppang HS, Danielsen HE, Reith A. DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 2001;344:1270-1278, 1323-1326 [comment].
156. Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia [Comments]. Clin Cancer Res 2000;6:357-362.
157. Khan AJ, King BL, Smith BD, et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res 2002;8:540-548.
158. Meric F, Hung MC, Hortobagyi GN, Hunt KK. HER2/neu in the management of invasive breast cancer. J Am Coll Surg 2002;194:488-501.
159. Lotti LV, Di Lazzaro C, Zompetta C, Frati L, Torrisi MR. Surface distribution and internalization of erbB-2 proteins. Exp Cell Res 1992;202:274-280.
160. Sorkin A, Di Fiore PP, Carpenter G. The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. Oncogene 1993;8:3021-3028.
161. Yarden Y. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Proc Natl Acad Sci U S A 1990;87:2569-2573.
162. Gilboa L, Ben-Levy R, Yarden Y, Henis YI. Roles for a cytoplasmic tyrosine and tyrosine kinase activity in the interactions of Neu receptors with coated pits. J Biol Chem 1995;270:7061-7067.
163. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-2777.